These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 6819017)

  • 21. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Thalassemic cardiopathy: serial echocardiographic evaluation].
    Bosi S; Spinolo L; Cavallini B; Guadagni C; Lama A; Santarelli R; Baccini C
    G Clin Med; 1982 Apr; 63(4):248-54. PubMed ID: 7128980
    [No Abstract]   [Full Text] [Related]  

  • 24. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 25. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N; Ullrich D; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1985 Nov; 110(48):1848-51. PubMed ID: 4064938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical management of beta-thalassemia.
    Lerner N
    Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapy of HBsAg-negative chronic active hepatitis in transfusion-dependent thalassemia major.
    De Virgiliis S; Argiolu F; Rais M; Cossu P; Toccafondi C; Sanna G; Cornacchia G; Nucaro A; Ferreli A; Cao A
    Birth Defects Orig Artic Ser; 1982; 18(7):355-60. PubMed ID: 6819018
    [No Abstract]   [Full Text] [Related]  

  • 29. Thalassemia.
    Brown EB
    Prog Clin Biol Res; 1983; 127():33-42. PubMed ID: 6889403
    [No Abstract]   [Full Text] [Related]  

  • 30. Editorial retrospective. Iron loading in thalassemia--five years with the pump.
    Weatherall DJ; Pippard MJ; Callender ST
    N Engl J Med; 1983 Feb; 308(8):456-8. PubMed ID: 6823257
    [No Abstract]   [Full Text] [Related]  

  • 31. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P; Giua R; De Marco S; Bonetti MG; Amurri B; Masi C; Lazzari G; Rizzo C; Cervellera M; Peluso A
    Haematologica; 1995; 80(5):398-404. PubMed ID: 8566878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron chelation in thalassemia.
    Pippard MJ
    Birth Defects Orig Artic Ser; 1988; 23(5B):35-40. PubMed ID: 3390560
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B.
    Bayraktar Y; Saglam F; Temizer A; Uzunalimodlu B; van Thiel DH
    Hepatogastroenterology; 1998; 45(24):2322-7. PubMed ID: 9951916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C; Rachmilewitz EA
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
    Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
    [No Abstract]   [Full Text] [Related]  

  • 36. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
    Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G
    Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996
    [No Abstract]   [Full Text] [Related]  

  • 37. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normal serum ferritin levels following prolonged desferrioxamine therapy: Melbourne experience.
    Matthews RN
    Birth Defects Orig Artic Ser; 1988; 23(5B):117-22. PubMed ID: 3390533
    [No Abstract]   [Full Text] [Related]  

  • 40. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.
    Schettini F; Mautone A; Cavallo L; Altomare M; Montagna O; Dell'Edera L
    Acta Haematol; 1981; 66(2):96-101. PubMed ID: 6794319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.